72.11.Z - Research and experimental development on biotechnology
70.22.Z - Business and other management consultancy activities
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
72.20.Z - Research and experimental development on social sciences and humanities
73.20.Z - Market research and public opinion polling
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
77.40.Z - Leasing of intellectual property and similar products, except copyrighted works
85.5 - Other education
85.6 - Educational support activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Profit (loss) on sale | 0,9 | 0,8 | 1,4 | 74 |
Gross profit (loss) | 0,9 | 0,8 | 1,4 | 74 |
EBITDA | 0,9 | 0,8 | 1,4 | 74 |
Short time liabilities | 1,9 | 2,5 | 1,6 | -34,9 |
Other operating costs | 0 | 0 | 0 | 0 |
Equity capital | -0,2 | 0,6 | 1,9 | 206,2 |
Operating profit (EBIT) | 0,9 | 0,8 | 1,4 | 74 |
Assets | 1,7 | 3,1 | 3,5 | 13,6 |
Net profit (loss) | 0,7 | 0,8 | 1,3 | 58,3 |
Cash | 0,2 | 0,4 | 2,5 | 522,4 |
Net income from sale | 2,5 | 2,4 | 2,5 | 4,2 |
Liabilities and provisions for liabilities | 1,9 | 2,5 | 1,6 | -34,9 |
Working assets | 0,7 | 2,1 | 2,5 | 20,2 |
Other income costs | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -358,8 | 130,3 | 67,3 | -63 |
Equity capital to total assets | -11,3 | 20,1 | 54,2 | 34,1 |
Gross profit margin | 35 | 33,7 | 56,3 | 22,6 |
EBITDA Margin | 35 | 33,7 | 56,3 | 22,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 276 | 375 | 235 | -140 |
Current financial liquidity indicator | 0.358146071434021 | 0.8464033603668213 | 1.5618106126785278 | 0,8 |
Net dept to EBITDA | -0.2085617482662201 | -0.48702746629714966 | -1.742209792137146 | -1,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane